Tumor Treating Fields (TTFields, 200 kHz)

Drug identity has not yet been verified against registry records

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive GlioblastomaNCT06061809IBRXPhase 2Active not recruiting2029-12-31Estimated

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.